
Danaher beats Q2 earnings estimates but shares drop on biotech revenue worries
Danaher Corporation reported stronger-than-expected Q2 2026 earnings and revenue, driven by its Life Sciences segment, with EPS of $1.94 and revenue of $6.27 billion beating estimates. However, the stock fell nearly 12% in premarket trading due to in...

